Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1997 1
2007 1
2012 1
2013 2
2014 1
2015 1
2017 1
2019 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
Patnaik MM, Tefferi A. Patnaik MM, et al. Am J Hematol. 2021 Mar 1;96(3):379-394. doi: 10.1002/ajh.26090. Epub 2021 Jan 28. Am J Hematol. 2021. PMID: 33428785 Free article. Review.
DIAGNOSIS: MDS-RS is a lower risk MDS, with single or multilineage dysplasia (MDS-RS-SLD/MLD), <5% bone marrow (BM) blasts, <1% peripheral blood blasts and 15% BM RS (5% in the presence of SF3B1 mutations). ...Luspatercept, a first-in-class erythroid maturation agent …
DIAGNOSIS: MDS-RS is a lower risk MDS, with single or multilineage dysplasia (MDS-RS-SLD/MLD), <5% bone marrow (BM) blasts, <1% …
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
Patnaik MM, Tefferi A. Patnaik MM, et al. Am J Hematol. 2019 Apr;94(4):475-488. doi: 10.1002/ajh.25397. Epub 2019 Jan 24. Am J Hematol. 2019. PMID: 30618061 Free PMC article. Review.
DIAGNOSIS: MDS-RS is a lower-risk MDS, with single or multilineage dysplasia (SLD/MLD), <5% bone marrow (BM) blasts and 15% BM RS (5% in the presence of SF3B1 mutations). ...The advent of luspatercept, a first-in-class erythroid maturation agent will tremendously boost …
DIAGNOSIS: MDS-RS is a lower-risk MDS, with single or multilineage dysplasia (SLD/MLD), <5% bone marrow (BM) blasts and 15% BM RS …
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.
Patnaik MM, Tefferi A. Patnaik MM, et al. Am J Hematol. 2017 Mar;92(3):297-310. doi: 10.1002/ajh.24637. Am J Hematol. 2017. PMID: 28188970 Free PMC article. Review.
DIAGNOSIS: MDS-RS is a lower risk MDS, with single or multilineage dysplasia (SLD/MLD), <5% bone marrow (BM) blasts and 15% BM RS (5% in the presence of SF3B1 mutations). ...Both diseases have a low risk of leukemic TREATMENT: Anemia and iron overload are complications …
DIAGNOSIS: MDS-RS is a lower risk MDS, with single or multilineage dysplasia (SLD/MLD), <5% bone marrow (BM) blasts and 15% BM RS …
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.
Della Porta MG, Travaglino E, Boveri E, Ponzoni M, Malcovati L, Papaemmanuil E, Rigolin GM, Pascutto C, Croci G, Gianelli U, Milani R, Ambaglio I, Elena C, Ubezio M, Da Via' MC, Bono E, Pietra D, Quaglia F, Bastia R, Ferretti V, Cuneo A, Morra E, Campbell PJ, Orazi A, Invernizzi R, Cazzola M; Rete Ematologica Lombarda (REL) Clinical Network. Della Porta MG, et al. Leukemia. 2015 Jan;29(1):66-75. doi: 10.1038/leu.2014.161. Epub 2014 May 20. Leukemia. 2015. PMID: 24935723
The severity of granulocytic and megakaryocytic dysplasia significantly affected survival. A close association was found between ring sideroblasts and SF3B1 mutations, and between severe granulocytic dysplasia and mutation of ASXL1, RUNX1, TP53 and SRSF2 gene …
The severity of granulocytic and megakaryocytic dysplasia significantly affected survival. A close association was found betwe …
Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.
Senent L, Arenillas L, Luño E, Ruiz JC, Sanz G, Florensa L. Senent L, et al. Haematologica. 2013 Apr;98(4):568-75. doi: 10.3324/haematol.2012.071449. Epub 2012 Oct 12. Haematologica. 2013. PMID: 23065505 Free PMC article.
The degree of agreement for the percentages of blasts in bone marrow and peripheral blood, ring sideroblasts in bone marrow, and erythroid, granulocytic and megakaryocytic dysplastic cells was strong (P<0.001 in all instances). ...In conclusion, the reproducibility of t …
The degree of agreement for the percentages of blasts in bone marrow and peripheral blood, ring sideroblasts in bone marrow, and erythroid, …
Differential diagnosis of myelofibrosis based on WHO 2008 criteria: acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis.
Bae E, Park CJ, Cho YU, Seo EJ, Chi HS, Jang S, Lee KH, Lee JH, Lee JH, Suh JJ, Im HJ. Bae E, et al. Int J Lab Hematol. 2013 Dec;35(6):629-36. doi: 10.1111/ijlh.12101. Epub 2013 May 22. Int J Lab Hematol. 2013. PMID: 23693053
RESULTS: APMF showed hyperplasia of all three lineages, increase in megakaryocyte count with dysplasia and frequent abnormal karyotypes. AMKL-MF was associated with elevated BM blast counts, decreased BM megakaryocyte count with rare megakaryocytic …
RESULTS: APMF showed hyperplasia of all three lineages, increase in megakaryocyte count with dysplasia and frequent abnormal k …
Peripheral blood picture in primary hypocellular refractory anemia and idiopathic acquired aplastic anemia: an additional tool for differential diagnosis.
Elghetany MT, Hudnall SD, Gardner FH. Elghetany MT, et al. Haematologica. 1997 Jan-Feb;82(1):21-4. Haematologica. 1997. PMID: 9107077 Review.
METHODS: PB findings in ten cases of PHRA, which are selected based on the following: less than 30% cellularity, multilineage dysplasia and/or clonal cytogenetic abnormality, are compared to ten cases of classic AA. The PB is examined for automated parameters, differential …
METHODS: PB findings in ten cases of PHRA, which are selected based on the following: less than 30% cellularity, multilineage dysplasia …
Diagnosis and treatment of the preleukemic syndrome (hemopoietic dysplasia).
Linman JW. Linman JW. Geriatrics. 1978 Jan;33(1):40-7. Geriatrics. 1978. PMID: 620925
This syndrome, which has been termed the "preleukemic syndrome" or "hemopoietic dysplasia", appears to be a stage in a multiphasic myeloproliferative disorder, rather than a separable disease with a propensity to develop leukemia. ...The panmyelopathy begins as a red cell …
This syndrome, which has been termed the "preleukemic syndrome" or "hemopoietic dysplasia", appears to be a stage in a multiphasic my …
Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification.
Matsuda A, Germing U, Jinnai I, Iwanaga M, Misumi M, Kuendgen A, Strupp C, Miyazaki Y, Tsushima H, Sakai M, Bessho M, Gattermann N, Aul C, Tomonaga M. Matsuda A, et al. Leukemia. 2007 Apr;21(4):678-86. doi: 10.1038/sj.leu.2404571. Epub 2007 Feb 1. Leukemia. 2007. PMID: 17268513
In the criteria of refractory cytopenia with multilineage dysplasia (RCMD) according to the WHO (World Health Organization) classification, the frequency threshold concerning dysplasia of each lineage was defined as 10%. ...
In the criteria of refractory cytopenia with multilineage dysplasia (RCMD) according to the WHO (World Health Organization) classific …